Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma

NCT01900327 is registered in ClinicalTrials.gov with Universitätsklinikum Hamburg-Eppendorf as lead sponsor.

NCT NCT01900327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01900327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2014
Completion date
July 31, 2017
Enrollment
32 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer